Bronchiectasis is a morphological term used to describe abnormal irreversibly dilated and often thick walled bronchi. This traditional definition evolved from Laënnec’s original description in 1819 of ectatic bronchi in pathological specimens and implies that the disease process is lifelong and irreversible. Since this time the term has been used more widely to describe both clinical and radiological disease entities. However, the precise relationship between the clinical features, radiological, and histological findings in children is unknown.

Bronchiectasis not caused by cystic fibrosis (CF) is often perceived to be rare in western societies, but remains an important cause of chronic suppurative lung disease in the developing world. A decline in hospital admission rates for paediatric bronchiectasis in the UK has been noted since the 1950s. This has been attributed to improved sanitation and nutrition, introduction of childhood immunisation, particularly against pertussis and measles, and the early and frequent use of antibiotics. Quantitative estimates of the prevalence of bronchiectasis in children worldwide are lacking.

The advent of high resolution computed tomographic (HRCT) scanning, a highly sensitive non-invasive technique, has greatly improved our ability to recognise this condition which is both permanent and progressive. This term is not necessarily appropriate for all paediatric patients for whom we suggest an alternative nomenclature.

Methods
A retrospective case note review was conducted of 93 consecutive patients with bronchiectasis confirmed by HRCT scanning. The children constituted 9.6% of all new referrals between November 1996 and May 2002. A radiological diagnosis of bronchiectasis was made on the HRCT scan if any of the following diagnostic criteria was present: 10

- cross sectional diameter of one or more bronchi greater than that of the accompanying pulmonary artery;
- mucoid impaction within a dilated bronchus;
- non-tapering bronchi in cuts parallel to the direction of travel;
- bronchi visible adjacent to the non-mediastinal pleura.

The HRCT diagnosis was made by a consultant cardithoracic radiologist who was aware of the clinical suspicion of bronchiectasis but not the site of any suspected abnormality. A chest radiograph report was obtained for each child, where
available, taken up to a year before the HRCT scan. Most of the children were referred by paediatricians from district general hospitals or from primary care practices in the Northern Region. Children with primary immune deficiencies or following heart transplantation came from a wider geographical area.

Chest radiographs were reported by a number of different radiologists. As it was not possible to establish the individual criteria adopted by each radiologist for suspecting bronchiectasis, the reports were divided into three broad categories:

- normal;
- abnormal, with no report of bronchial dilation and not containing the phrase “suggestive of bronchiectasis”;
- abnormal, with a report of bronchial dilation and/or containing the phrase “suggestive of bronchiectasis” with location specified.

All patients were investigated to determine the aetiology at the discretion of the attending paediatrician. Investigations included bronchoscopy, measurement of serum immunoglobulins (Igs), IgG subclasses, specific antibody responses to tetanus toxoid, and to the capsular polysaccharides of Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae, and nasal brushings for ciliary beat frequency and electron microscopy. Bacterial culture of cough swab, sputum, or bronchoalveolar lavage (BAL) fluid was obtained in all patients. Sweat tests were performed in all cases unless bronchiectasis was limited to one lobe and there was an obvious associated clinical diagnosis, or if the child had received a cardiac transplant.

RESULTS

The male to female ratio of the 93 cases was 2:1. Table 1 shows their ages at symptom onset and establishment of the HRCT diagnosis of bronchiectasis. The median time to HRCT diagnosis from symptom onset was 3.0 years (range 0.1–14.8). This represents either a delay in presentation or in referral, as the median time to HRCT diagnosis from first tertiary centre appointment was only 0.2 years (range 0–4.5).

The most common referral diagnosis of asthma in 45 cases (49%, fig 1) was often reported to be “difficult to control”. This diagnosis was felt to be incorrect on clinical review and lung function testing in 39 cases (87%). Subsequent withdrawal of anti-asthma medication was not associated with clinical deterioration in any child. Table 2 shows the final associated diagnoses for the 93 children following investigation.

The most common association was of a previous pneumonic illness. This occurred before the age of 1 year in 16 of 34 cases (47%). A familial syndrome occurred in two siblings in a family where two generations were affected by bronchiectasis in association with retinitis pigmentosa, in whom the genetic defect is unknown.

Major immune deficiency was the principle referring diagnosis for five children (chronic granulomatous disease in four and agammaglobulinaemia in one). Five children were immunosuppressed following cardiac transplantation and one child had been treated for acute lymphoblastic leukaemia. Immunoglobulins were measured in 80 children and five were shown to have an IgA deficiency. Of the 71 children for whom IgG subclasses were measured, 10 had an IgG2 deficiency and one had low IgG2 and IgG3 levels. Low levels of specific antibodies were detected in 55 children (75%). A good response to appropriate vaccination occurred in 29 children. A primary diagnosis of specific antibody deficiency to capsulated bacteria was made in four cases and of common variable immune deficiency in one case.

Nasal ciliary beat frequency was measured in 46 children. As it was not possible to establish the individual criteria adopted by each radiologist for suspecting bronchiectasis, the reports were divided into three broad categories:

- normal;
- abnormal, with no report of bronchial dilation and not containing the phrase “suggestive of bronchiectasis”;
- abnormal, with a report of bronchial dilation and/or containing the phrase “suggestive of bronchiectasis” with location specified.

Table 1 Median ages at HRCT diagnosis and symptom onset

<table>
<thead>
<tr>
<th>Age of HRCT scan diagnosis (years)</th>
<th>No (%)</th>
<th>Median</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5</td>
<td>31 (34)</td>
<td>7.2</td>
<td>1.6–18.8</td>
</tr>
<tr>
<td>5–&lt;10</td>
<td>33 (36)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥10</td>
<td>28 (30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age of symptom onset (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5</td>
<td>66 (81)</td>
<td>1.1</td>
<td>0–16</td>
</tr>
<tr>
<td>5–&lt;10</td>
<td>12 (15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥10</td>
<td>3 (4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1 Referral diagnosis for 93 cases of non-CF bronchiectasis.

Table 2 Aetiology of non-CF bronchiectasis in 93 children

<table>
<thead>
<tr>
<th>Aetiology</th>
<th>No (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-pneumonic</td>
<td>28 (30)</td>
</tr>
<tr>
<td>Immunodeficiency/immunosuppression</td>
<td>19 (21)</td>
</tr>
<tr>
<td>Idiopathic</td>
<td>17 (18)</td>
</tr>
<tr>
<td>Associated with bronchiolitis obliterans</td>
<td>8 (9)</td>
</tr>
<tr>
<td>Congenital lung abnormality</td>
<td>4 (5)</td>
</tr>
<tr>
<td>Chronic aspiration</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Post-pneumonic + congenital lung abnormality</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Familial syndrome</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Post-pneumonic + immunodeficient</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Hypersecretory asthma (right middle lobe syndrome)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Associated with primary eosinophilic oesophagitis</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Primary ciliary dyskinesia</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Immunodeficient + chronic aspiration</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Immunodeficient + congenital lung abnormality</td>
<td>1 (1)</td>
</tr>
</tbody>
</table>

www.thoraxjnl.com
Figure 2  Respiratory pathogens isolated from 93 children with non-CF bronchiectasis.

Figure 3 illustrates the agreement between the chest radiography and HRCT reports in diagnosing bronchiectasis and the lobe(s) affected. In 12 children no radiography report was available in the year preceding the HRCT scan. The radiography report agreed exactly with the HRCT report in only five cases (5%).

Repeat HRCT scans were performed in 18 cases a minimum of 18 months after HRCT diagnosis and initiation of treatment (range 18 months–5 years). The repeat scans were performed on clinical grounds. Complete radiological resolution of bronchiectasis on HRCT scan was reported in six cases (four post-pneumonic, two idiopathic) and in one case of post-pneumonic bronchiectasis the radiological appearance was improved. Radiological progression of the disease was reported in five cases (two immunocompromised, two post-pneumonic, one hypersecretory asthma/right middle lobe syndrome) and the appearances were unchanged in the remaining six (two immunocompromised, one obliterate bronchiolitis, two post-pneumonic, one idiopathic).

DISCUSSION

HRCT defined non-CF bronchiectasis is not an uncommon problem in our referral population. The 93 cases described constitute 9.6% of all new referrals to a tertiary respiratory paediatric referral centre over a period of 5.5 years, which represents a 10-fold higher rate of diagnosis than that described by Nikolaizik and Warner in 1994.19 This increase can largely be attributed to the introduction of HRCT scanning to investigate chronic respiratory illness in children in recent years. A crude estimate of the prevalence of HRCT defined non-CF bronchiectasis in children under 17 years of age in the Northern Region (excluding South Cleveland) is one in 5800 based on the average annual birth rate of 31 500. It is acknowledged that this will include children at the milder end of the disease spectrum, as a single dilated bronchus of cross sectional diameter greater than that of its accompanying pulmonary artery is sufficient to satisfy the diagnostic criteria for HRCT bronchiectasis. It is anticipated, however, that there will also be a significant number of undiagnosed cases in the community.

Onset of respiratory symptoms is reported at a young age (median 1.1 years), but there is a pronounced delay from onset to diagnosis by HRCT scan (median 3.0 years). We believe that this may be due to the misdiagnosis of asthma in children with cough and no wheeze who had been labelled as having “cough variant asthma”. Our findings support the assertion of McKenzie20 who has previously highlighted the potential inaccuracy of a diagnosis of asthma when based on the symptom of cough alone.

The chest radiography report was in exact agreement with the HRCT scan report for diagnosis and affected lobe(s) in only five cases (5%). The chest radiograph was reported as normal in a further 12 children (13%) with HRCT confirmed bronchiectasis. We acknowledge the limitations of comparison of radiographic reports made by multiple radiologists with an HRCT scan report made by a single cardiothoracic radiologist. We also accept that HRCT diagnosis of bronchiectasis is subject to some observer bias. Nevertheless, these findings suggest that the chest radiograph is of little diagnostic value in children with bronchiectasis, and that the report of a normal chest radiograph should not detract from further investigation of children with persistent respiratory symptoms who have evidence of chronic bacterial endobronchial infection.

Clarification of the diagnosis of bronchiectasis has major practical implications for the management of these patients. Revision of the diagnosis of asthma allows discontinuation of unnecessary medications with significant clinical and economic benefit. A diagnosis of bronchiectasis allows rational treatment with antibiotics and physiotherapy to be instituted. Studies in adults with bronchiectasis have shown that onset of sputum production commenced before the age of 10 years in 40% of cases, suggesting that the onset of disease is often in childhood.21 Early diagnosis and treatment may improve the long term prognosis as it is known that aggressive treatment with antibiotics and physiotherapy slows disease progression of bronchiectasis in patients with CF and in children with primary ciliary dyskinesia.22,23 We have also shown a resolution of the radiological changes of bronchiectasis on the HRCT scan in six cases following prompt management of respiratory exacerbations and regular physiotherapy a minimum of 18 months after initial diagnosis. HRCT resolution only occurred in patients in whom the aetiology was either non-progressive or idiopathic. These findings raise questions as to the nature of the relationship between radiological findings and the histological changes of bronchiectasis in children.

The pathogenesis of bronchiectasis is incompletely understood. The most commonly proposed pathophysiological mechanism is the “vicious cycle theory” whereby an initial insult damages the respiratory tract resulting in impaired mucociliary clearance. This leads to chronic bacterial infection associated with a persistent inflammatory response producing fibrotic changes.24 The initial trigger is often infective although other factors must also be considered, particularly those that predispose to bronchial and pulmonary infection including immunodeficiency and anatomical abnormalities of the airways. In this series of patients the
most commonly reported initial insult appears to be a previous pneumonic illness which accounted for 30% of our cases. This is in contrast to 66–69% of cases in a series in the 1960s when conditions such as measles, pertussis and tuberculosis were more prevalent.19-20 It is known that a pneumonia occurring at the time of rapid lung development, during the first 3 years of life, may impair subsequent growth and lung function.21,22 Sixteen (47%) of our cases with a reported pneumonia experienced their illness before the age of 1 year, suggesting that immunological immaturity may be an important prognostic factor.

In our series H influenzae and S pneumoniae were isolated most commonly (fig 3). This differs from the bacteriological pattern seen in established bronchiectasis in adults where P aeruginosa is a major pathogen.23

Low levels of specific antibodies were commonly encountered in this series; however, the good response to vaccines seen in the majority suggests that most children do not have a significant primary immunological problem. The relationship between low levels of bacterial antibodies and the bronchiectatic process remains uncertain.

It is clear from our series that the term “bronchiectasis”, which describes a progressive and irreversible disease process, is often imprecise when referring solely to radiological changes in this age group. As the term bronchiectasis has both prognostic and therapeutic implications, we suggest that we should now attempt to improve the nomenclature of this group of disorders in children. We propose that chronic suppurative lung disease may be viewed as a disease spectrum comprising three interrelated components: pre-bronchiectasis, HRCT bronchiectasis, and established bronchiectasis (fig 4, box 1). Children with pre-bronchiectasis are presumably suffering from a form of chronic bronchitis, but we suggest that this term should be avoided as it differs from the classic form of smoking related chronic bronchitis seen in adults. Persistent endobronchial infection in the developing child appears to be associated with the subsequent development of bronchiectasis, whereas this does not appear to be the case for adult patients with smoking related chronic bronchitis.

Long term epidemiological studies will be required to establish details of the interrelationships and prognoses for these three disease entities.

**Box 1 Proposed definitions for the components of chronic suppurative lung disease in childhood**

**Pre-bronchiectasis**
Chronic or recurrent bacterial endobronchial infection which may be associated with non-specific changes such as bronchial wall thickening on the HRCT scan. This condition may persist, resolve, or progress to “HRCT bronchiectasis”.

**HRCT bronchiectasis**
The clinical features are associated with HRCT evidence of bronchial dilation. This entity may persist, progress to established bronchiectasis, return to a pre-bronchiectatic state, or resolve entirely.

**Established bronchiectasis**
The HRCT findings have not resolved after a significant time period (we suggest 2 years). This condition should then be regarded as irreversible.

**REFERENCES**
The need to redefine non-cystic fibrosis bronchiectasis in childhood

K M Eastham, A J Fall, L Mitchell and D A Spencer

Thorax 2004 59: 324-327
doi: 10.1136/thx.2003.011577

Updated information and services can be found at:
http://thorax.bmj.com/content/59/4/324

References
This article cites 20 articles, 7 of which you can access for free at:
http://thorax.bmj.com/content/59/4/324#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Child health (843)
- Radiology (diagnostics) (812)
- Pneumonia (infectious disease) (579)
- Pneumonia (respiratory medicine) (562)
- TB and other respiratory infections (1273)
- Asthma (1782)
- Bronchiolitis (112)
- Bronchitis (235)
- Ear, nose and throat/otolaryngology (218)
- Interstitial lung disease (559)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/